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Objectives: To evaluate the short- and long-term effi-
cacy of self-expanding metal stents (SEMSs) in patients
with colorectal obstruction and incurable cancer and the
related factors that affect outcomes.
Design: Retrospective analysis of SEMS placement for
incurable colorectal obstruction in a 3-year period.
Setting: Five tertiary care endoscopic centers.
Patients and Intervention: Consecutive patients
(N=201) undergoing stenting for incurablemalignant ob-
struction.
Main Outcome Measurements: Clinical and tech-
nical success of stenting, complications rate, and factors
affecting outcomes.
Results: Technical success was achieved in 184 of 201
patients (91.5%) and clinical success occurred in 165 of
184 patients (89.7%; 82.1% of 201 patients). Technical
and clinical failures were more frequent in extrinsic and
long colorectal stenoses. Overall, 165 patients had nor-
mal bowel movements during follow-up (mean [SD],
115.5 [100.3] days; range, 1-500days), 15 developed com-
plications, 127 had a functioning SEMS at the time of
death, and 23 were alive at completion of the study.
Twenty-four (11.9%) major complications occurred: 11
migrations, 12 perforations, and 1 reobstruction. Migra-
tion of SEMSswas associatedwith stent diameter less than
25 mm. Bevacizumab therapy increased the risk of per-
foration by 19.6-fold. Karnofsky performance status of
50 or less was associated with shorter survival and a 3.7-
fold higher risk of death within 6 months after the stent
was placed.
Conclusions: The use of SEMSs is safe and effective for
palliation of incurablemalignant colonic obstruction; ap-
proximately 75% of patients with SEMSs are able to avoid
colostomy.
Arch Surg. 2011;146(10):1157-1162
O NE-QUARTER OF PATIENTSwith colorectal cancer(CRC)developbowel ob-struction.1 In approxi-mately 30%of these indi-
viduals, curative resection is not feasible
because of advanced disease and comor-
bidities. Surgical intervention in these pa-
tients usually results in later creation of co-
lostomy,which cannot be reversed in up to
50% of the cases.2 Self-expandable metal
stents (SEMSs) represent a valid alterna-
tive to operations, either as a bridge to sur-
gical intervention or for palliation.
Use of SEMSs has a 90% success rate,
acceptable complication rate, and negli-
gible incidence ofmortality.3-7Onceplaced,
a SEMS relieves obstruction, avoiding co-
lostomy, with improved quality of life un-
til death in approximately 85% of pa-
tients.3,7-10 However, approximately 25%
of patients with this stent develop com-
plications, such as perforation, occlu-
sion, and migration, which are usually
early events.3,4,6 The endoscopist’s expe-
rience, tumor location, stricture predila-
tion, and stent characteristics are closely
related to the development of early com-
plications.3,4,6 Late complications are likely
the result of several factors involving the
interaction between the SEMS and host,
such as stent characteristics, tumor loca-
tion, tumor progression, different treat-
ments, and length of patient survival.3,4,6
Reduction in the early complication rate
can be achieved by improving the inser-
tion technique and the selection of appro-
priate patients and lesions. Development
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of late complications is often unpredictable. Treatment
with bevacizumab has been related to an increased risk
of perforation in patients with SEMSs.6,11,12 Theoreti-
cally, the longer the stent remains in the colon, the higher
the likelihood that a complication will develop. A SEMS
theoretically should be placed in patients with either high
surgical risk or short life expectancy. Therefore, while
managing care for a patient with incurable CRCwho de-
velops an obstruction, we need to carefully consider all
factors that are likely to influence both survival and pos-
sible stent-related complications.
The objective of this study was to evaluate the short-
and long-term efficacy of SEMSs in a large series of pa-
tients with colorectal obstruction and incurable cancer.
Different factors affecting the immediate success of SEMSs,
as well as early and late complications, were analyzed to
identify useful criteria in choosing between an opera-
tion and use of a SEMS for the care of patients with in-
curable cancer who develop an obstruction.
METHODS
STUDY DESIGN
We retrospectively evaluated all patients with incurable can-
cer and colonic obstruction consecutively undergoing SEMS
placement in 5 Italian endoscopic centers from January 11, 2007,
to December 20, 2009. All patients were diagnosed as having
colorectal obstruction due to incurable CRC or extracolonic
cancer, confirmed by computed tomography and/or colonos-
copy. Obstruction was considered to be complete if the pa-
tients were unable to pass stool and gas. Obstruction was con-
sidered to be partial if patients were symptomatic but able to
pass gas or had paradoxical diarrhea.
Patients were identified retrospectively by using a dedi-
cated database in each center. After approval by the ethics com-
mittee of each institution, the data were retrieved, pooled, and
reviewed by one of the authors (G.M., M.dB., L.F., A.R., and
E.M.), with all patient data remaining confidential.
STENTING TECHNIQUE
The SEMSs were inserted in the conventional manner by 1 of
2 endoscopists in each center.13 All the endoscopists were ex-
perts in therapeutic endoscopy. To minimize the risk of per-
foration, dilation of the stricture was avoided.
DEFINITIONS
The patient was considered to have incurable cancer when cu-
rative resection of metastatic disease was impossible because
of extended liver metastases (bilobar multiple lesions, involve-
ment of the hilum or 3 major hepatic veins, or remnant liver
volume 30% after hepatectomy) or extrahepatic disease.
Technical success was defined as successful placement of
the SEMS, with correct deployment and positioning at the level
of the stenosis, determined with radiologic procedures. Clini-
cal success was defined as complete colonic decompression
within 72 hours after SEMS insertion, clinically and radiologi-
cally assessed. Deathwas considered to be related to SEMS com-
plications if it occurred within 7 days after insertion.
Major complications were events leading to surgical or en-
doscopic reintervention or requiring admission to the inten-
sive care unit. Perforation, stent obstruction, andmigrationwere
considered to bemajor complications.Mild complications were
events leading to rehospitalization or prolonged hospital stay
without fulfilling the major complications criteria.
PATIENT ASSESSMENT AND FOLLOW-UP
Before SEMS placement, a routine workup, including com-
puted tomography of the abdomen and chest, as well as calcu-
lation of Karnofsky performance status (KPS), was con-
ducted.14 After successful placement of the stent, patients were
monitored in the outpatient clinic until death occurred, an op-
eration was performed, or a complication developed. No pa-
tient was lost to follow-up. For patients who missed periodic
clinic visits, data were obtained by means of telephone calls to
the patient or the closest relative and by reviewingmedical rec-
ords. Technical and clinical success of the SEMSs, occurrence
and timing of complications, and need for surgical interven-
tion were analyzed.
Early outcomes were assessed 72 hours after insertion of the
SEMS; these included (1) successful placement, both techni-
cal and clinical; (2) unsuccessful placement due to technical
or clinical failure; and (3) development of a major complica-
tion during SEMS placement (immediate complication) or dur-
ing the first 24 to 72 hours after its placement (early compli-
cation). Late outcomes were assessed at the end of follow-up
and were identified by development of a major complication,
surgical or endoscopic reintervention, or death of the patient.
STATISTICAL ANALYSIS
Variables analyzed included patient characteristics, tumor
characteristics, technical details, and chemotherapy per-
formed. Univariate descriptive statistics at baseline were com-
puted for the entire patient group. Association between base-
line characteristics and technical and clinical success, as well
as early and late complications, was analyzed by means of the
2 test; the odds ratio (OR) and 95% confidence interval (CI)
were calculated. Time to considered end points (occurrence
of complications, surgical intervention, or death) was mea-
sured. Kaplan-Meier survival analysis was performed to calcu-
late the cumulative rate of clinical success, such as sustained
relief of obstruction and lack of complications. Statistical sig-
nificance was defined as P .05. Analyses were performed
using commercial software (SPSS package, version 13; SPSS
Inc, Chicago, Illinois).
RESULTS
The study flowchart is depicted in Figure 1. During a
3-year period, 242 patientswith colorectal obstruction un-
derwent SEMS placement. One hundred five patients had
complete bowel obstruction and underwent urgent stent-
ing. Forty-one SEMSs were used as a bridge to an opera-
tion and were clinically successful in 36 patients who un-
derwent an elective operation 9.4(5.01) days (range, 4-21
days) later. In this subset of 36 patients, colostomywas re-
quired for only 14. The remaining 64 patients were con-
sidered to be unfit for surgical procedures at the subse-
quent workup, and a SEMS was the final palliation. One
hundred thirty-seven patients with partial bowel obstruc-
tion and advanced metastatic disease underwent SEMS
placement for palliation. The latter was the indication for
use of the stent in 201 patients.
Demographic and clinical characteristics of the pa-
tients are reported in Table 1. One hundred fifty-three
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patients were affected by primary CRC, 20 had devel-
oped anastomotic recurrence of CRC, and 28 had an ex-
trinsic compression due to extracolonic cancer. Thema-
jority of SEMSs were placed in the rectosigmoid colon
(Table 1). Overall, 204 stents were inserted in 191 pa-
tients. Insertion of a SEMS failed in 10 patients because
of the inability to place the guide wire across the steno-
sis. In 5 patients, 2 consecutive stents were placed in a
long stricture. A second stent was inserted in 8 patients
after migration of the first one. Characteristics of the
SEMSs are described in Table 2. One hundred eighty-
four patients (90.2%)were treatedwith uncovered stents,
which were placed through the endoscope in 169 pa-
tients (82.8%).
EARLY OUTCOME AND RELATED FACTORS
In the palliation group, technical success was achieved
in 184 of 201 patients (91.5%) at the first SEMS place-
ment. Reasons for technical failure were inability to place
a guide wire across the stenosis in 10 patients, stent mal-
position in 4, immediate perforation in 1, and failed stent
deployment in 2. All patients with stent failure under-
went an immediate operation for bowel decompression,
and 1 patient died. Clinical success with colonic decom-
pression was achieved in 165 of 184 patients (89.7%;
82.1% of the whole series). Causes of clinical failure in-
cluded early stent migration in 6 patients and stent mal-
position in 13.Migration of the SEMSwas treated by plac-
ing a new stent in 4 cases; 1 patient underwent an
operation. The sixth patient was treated conservatively
and died 5 days after SEMSmigration. Eleven of 13 cases
of stent malposition were decompressed surgically. The
clinical course of 2 other patients was complicated by ce-
cum blowout and colonic perforation. The first compli-
cation occurred 3 days after a failed attempt to place a
SEMS, and the patient died without further endoscopic
or surgical therapy. The second complication was diag-
nosed 4 days after stent placement, and the patient un-
derwent an operation. Table 3 reports factors corre-
lated with technical and clinical failure of the stents
according to univariate analysis. Strictures due to extrin-
sic compression and stenoses longer than 4 cmwere sig-
nificantly correlated with a higher failure rate.
LATE OUTCOME, COMPLICATIONS,
AND RELATED FACTORS
One hundred sixty-five patients who underwent success-
ful placement and functioning of a SEMS were followed
up for a mean of 115.5(100.3) days (range, 1-500 days)
until death or development of complications. Sustained
relief of obstructionwas achieved in 127 patients (77.0%)
until death. Twenty-three patientswere alive, with a func-
tioning stent, at the endof the studyperiod.Overall, 90.9%
of patients with successfully placed stents in our series
did not develop complications during follow-up. Accord-
ing to the Kaplan-Meier survival curves, the stent pat-
ency rate was 82.1% at 6months and 65.7% at 12months
(Figure 2).
Latemajor complications caused SEMS failure in 15 pa-
tients: 7 perforations, 1 reobstruction, 1 abscess, 1 recto-
vaginal fistula, and 5 stent migrations. Ten patients were
treated surgically: 9 received a permanent colostomy and
1 died. The remaining 5 patients (4 cases of stent migra-
tion and 1 of stent obstruction) were treated conserva-
tively by endoscopic placement of a new SEMS. Another
patient died 24hours after stenting; however, his deathwas
not considered to be stent related because of prompt co-
lonic decompression and no early complications.
Overall, 24 major complications (11.9%) were ob-
served in the study group. These included stent migra-
tion (11 [5.5%]); colonic perforation including an ab-
scess, a fistula, and a colonic blowout (12 [6.0%]); and
Died with functioning stent127
Alive at study’s end23
With complete obstruction
(urgent stenting)
105 With partial obstruction
(delayed stenting)
137
With technical success37
With clinical success36
Included in analysis201
With stent for palliation64 With primary palliation137With bridge to operation41
With successful stenting,
enter follow-up phase
165 With technical/clinical failure36
With complications during
follow-up
15
Patients with colon stenosis242
Figure 1. Study flowchart.
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reobstruction (1 [0.5%]). Nine complications were cor-
related with the procedure, and 15 occurred after suc-
cessful colonic decompression during follow-up. Thir-
teen of these late complications (86.7%) developedwithin
3 months, and 2 developed 6 months after stenting.
Development of complications did not correlate with
any of the analyzed variables (sex, symptoms, tumor type,
tumor location, length of the stenosis, and chemo-
therapy). Only small-caliber SEMSs (25 mm) were as-
sociated with stent migration (P=.002; OR, 7.0; 95%CI,
1.9-24.6). Overall, chemotherapy did not increase the risk
of complications; however, 50.0% (4 of 8) of patients
treated with bevacizumab experienced perforation. In
comparison, untreated patients, or those who received
standard chemotherapy, had a complication rate of 2.5%
(P .001; OR, 19.6; 95% CI, 5.9-64.5).
PATIENT SURVIVAL
The KPS significantly correlated with the survival of pa-
tients after placement of the SEMS. A KPS value of 50 or
less determined a significantly shorter mean survival
time (110.3 [140.1] vs 159.6[98.7] days, P .03) and
was associated with a 3.7-times (95% CI, 1.1- 9.7;
P=.02) higher risk of death within 6 months after place-
ment of the SEMS.
COMMENT
Colostomy provides relief of colonic obstruction sus-
tained until death in most patients with incurable neo-
plasia.3-7 However, surgical intervention is expensive and
may be associatedwith serious complications, even death.
A SEMS is likely to represent a valid alternative to sur-
gery in achieving effective colonic decompression.9,10 In
our series, immediate technical and clinical success rates
were 91.5% and 82.1%, respectively. These results are
similar to those reported in 2 systematic reviews3,4 and
correlate the results of single-center studies.5,6 These data
support the concept that colonic recanalization bymeans
Table 1. Demographic and Clinical Characteristics
of the Study Group
Characteristic No. (%)
Age, mean (SD) [range], y 68.86 (14.15) [21-100]
Sex
Male 110 (54.7)
Female 91 (45.3)
Karnofsky performance status, mean
(SD) [range]
55 (16.2) [20-80]
Occlusive symptoms
Total obstruction 64 (31.8)
Subtotal obstruction 137 (68.2)
Stenosis site
Rectosigmoid colon 134 (66.7)
Descending colon 14 (7.0)
Splenic flexure colon 15 (7.5)
Tranverse colon 9 (4.5)
Hepatic flexure 6 (3.0)
Ascending colon 3 (1.5)
Colorectal or colocolic anastomosis 20 (10.0)
Source of obstruction
Colorectal cancer 153 (76.1)
Recurrent colorectal cancer 20 (10.0)
Extrinsic compression due to extracolonic
cancer
28 (13.9)
Stenosis length, mean (SD) [range], cm 4.47 (1.9) [1-15]
Chemotherapy. No.a
Yes 74 (44.8)
No 91 (55.2)
Follow-up time until death or complication,
mean (SD) [range], d
115.5 (100.3) [1-500]
Patients who developed complications during
follow-up, No.
15
Patients who died during follow-up, No. 127
Patients without complications alive at the
end of the study, No.
23
aData total 165 because only patients who were successfully stented were
included.
Table 2. SEMS Characteristics
Characteristic No. (%)
Stent model, manufacturer
Bonastent, Alpharetta, Georgia 20 (9.8)
Hanaro, MiTech, Seoul, Korea 25 (12.3)
Evolution, Evolution Cook,
Limerick, Ireland
33 (16.2)
Ultraflex Precision, Boston
Scientific, Natick, Massachusetts
27 (13.2)
Wallflex, Boston Scientific 82 (40.2)
Wallstent, Boston Scientific 17 (8.3)
Stent length, mm
60 30 (14.7)
90 102 (50.0)
120 45 (22.1)
120 27 (13.2)
Stent diameter, mm
25 65 (31.9)
25 139 (68.1)
Insertion technique
Through the endoscope 169 (82.8)
Not through the endoscope 35 (17.2)
Uncovered/covered stent
Uncovered 184 (90.2)
Covered 20 (9.8)
Abbreviation: SEMS, self-expanding metal stent.
Table 3. Univariate Analysis of Factors Related
to Technical and Clinical Failure
Variable OR (95% CI) P Value
Technical Failure
Male sex 1.57 (0.50-4.40) .45
Complete occlusion 0.49 (0.18-1.30) .17
Extrinsic tumor 3.60 (1.60-10.70) .02
Rectosigmoid location 0.68 (0.18-2.40) .76
Length 4 cm 5.33 (1.40-20.10) .008
Clinical Failure
Male sex 1.80 (0.80-3.90) .10
Complete occlusion 0.68 (0.30-1.40) .30
Extrinsic tumor 4.35 (1.80-10.20) .001
Rectosigmoid location 0.77 (0.30-1.90) .60
Length 4 cm 2.40 (1.00-5.50) .03
Abbreviations: CI, confidence interval; OR, odds ratio.
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of SEMSs is effective, easy, and safe when performed by
experienced endoscopists.6 Accurate selection of pa-
tients for placement of a SEMS is crucial tomaximize im-
mediate success and minimize the risk of complica-
tions. According to our data, strictures due to extrinsic
compression and long stenoses are usually associatedwith
increased failure rates. Some authors3,4,6 have also dem-
onstrated that predilation of the stenosis and the inex-
perience of the endoscopistmay contribute to clinical fail-
ure and development of complications. All these factors
must be considered when deciding between placement
of a SEMS or an operation in the management of malig-
nant colonic obstruction.
Although short-term efficacy of SEMSs has been dem-
onstrated, the long-term results are still debated.12,15 Pa-
tientswith incurableCRChaveamedian survival time rang-
ing from 4 to 17 months.16 Those who receive stents have
a longer life expectancy and are likely to develop late com-
plications. Therefore, efforts should bemade to identify pa-
tients who receive better palliation with use of SEMSs and
those whomay benefit from surgical intervention. To our
knowledge, there has been only 1 prospective, random-
ized controlled study12 that compared the results of SEMSs
and operations for palliation of incurable malignant co-
lonic obstruction. This trial was closed prematurely be-
cause of the high number of serious adverse events in the
SEMS arm (6 perforations in 11 patients). However, non-
controlled studies6,17-19 reported that use of SEMSs pro-
vided sustained relief of obstructionuntil death in approxi-
mately 85% of patients with incurable obstructive CRC.
Small et al6 reported that 108 of 122 patients with stents
were free of obstruction until death. Karoui et al18 ob-
served a mean survival time of approximately 14 months
after SEMS placement, which was similar to that reported
in a group of patients treated with surgical procedures. In
our study, 90.9%of successfully stented patients diedwith
a functioning SEMS, and approximately 75.0% of all ob-
structed patients did not require colostomy, which likely
resulted in better quality of life, shorter hospitalizations,
and overall cost savings.9,10
Fifteen of the 165 patients in whom stenting was suc-
cessful developed late complications. An analysis of the
factors related to late complications shows a significant
association between SEMS migration and small-caliber
stents and between colonic perforation and beva-
cizumab therapy. It has been suggested6 that male pa-
tients and those with left-sided stenosis or complete ob-
struction developmore complications. Technical issues,
such as stent manufacturer and characteristics (covered
or uncovered, different shapes and materials) have been
advocated3,6,12,20 as possible explanations for different out-
comes. In our study, different SEMS models were used,
and no significant difference among SEMSs was ob-
served in both early and late outcomes.
After palliative stenting, many patients undergo che-
motherapy. This treatment determines tumor shrinkage
and can weaken the colonic wall. Both colon perfora-
tion and stent migration have been described6,12,15,18 in
patients treated with chemotherapy. In the study of van
Hooft et al,12 7 patients with stents were treated with che-
motherapy; 4 of them developed colonic perforation.
Karoui et al18 observed a 6% perforation rate in patients
undergoing chemotherapy after SEMS placement. In our
study, chemotherapy did not increase the complication
rate. Conversely, 4 of 8 patients who received beva-
cizumab developed a perforation, which suggests an in-
creased risk for perforation in this subset of patients. Few
patients in our series were treated with bevacizumab;
therefore, our results may not be statistically valid, rep-
resenting a possible error. However, these data are in ac-
cordance with the results of some recent reports6,11,21,22
and should be taken into account because the new
bevacizumab-based schedules of chemotherapy are in-
creasingly prescribed in patients with CRC.
Our hypothesis was that the longer patients survive
after stenting, the higher the likelihood of SEMS-related
major complications. Accordingly, patients selected for
palliative use of SEMSs should have a life expectancy
shorter than the expected stent patency time. In our se-
ries, patients with a KPS of 50 or less had a 3.7-times
higher chance of surviving less than 180 days and there-
fore were the best candidates for SEMSs. A higher KPS
should be an indication for palliative surgery. However,
we observed that the majority of complications devel-
oped within the first few days after SEMS insertion, with
only 2 complications occurring after 6 months. Accord-
ing to the Kaplan-Meier curve, 82.1% of stents main-
tained their patency at 6months and 65.7% of themwere
still functioning 1 year after placement. The fact that com-
plications do not occur in patients with long-term sur-
vival suggests that palliative use of SEMSsmay be a good
option for patients who are not seriously ill and have a
good life expectancy. Accurate patient selection and use
of SEMSs with proper characteristics are crucial for ob-
taining long-term efficacy of colorectal stents. If the SEMS
is not appropriate for the patient or the tumor, it could
be associated with the development of complications
within a few days after placement.
Our study design deserves some considerations. Its ret-
rospective fashion could represent a bias that should be
considered when interpreting the results. The multi-
center design carries both advantages and limitations. The
main limitation is theheterogeneity of thedata,whichorigi-
nate from5different centers andmay differ in terms of pa-
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Figure 2. Kaplan-Meier curve for clinical success of self-expanding medical
stents. Clinical success was 82.1% (95% CI, 0.73-0.91) at 180 days and
65.7% (95% CI, 0.40-0.91) at 1 year. CI indicates confidence interval.
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tient selection, endoscopic technique, SEMSsused, andmo-
dality of follow-up.However, the fact that demographic and
clinical characteristics as well as outcomes did not differ
significantly among theparticipating centers seems tomini-
mize theproblem.Themulticenterdesignof the studycould
be an advantage because the results are likely applicable
to the clinical routine of every tertiary endoscopic center.
Patients were enrolled for 3 years, which is shorter than in
other studies.6 Theparticipatingphysicianswere expert en-
doscopistswhohadalreadyplacednumerousSEMSs.There-
fore, poor results, usually related to the learning curve, are
not part of the study; this fact makes our data homoge-
neous over time.
In conclusion, our study further suggests that SEMSs
are an alternative to operations for patients with incur-
able malignant colorectal obstruction because approxi-
mately 75.0% of patients who receive the stents do not
require colostomy. In our clinical practice, we consider
SEMSs the first therapeutic option for these patients, es-
pecially if their KPS is 50 or less.We have identified some
factors associated with poor SEMS outcomes, such as ex-
trinsic and long stenoses, small-diameter stents, and be-
vacizumab treatment. All these factors have to be con-
sideredwhen choosing between SEMS and operation. The
long patency rate of most colorectal SEMSs suggests that
selection of the appropriate patient and stent is crucial
for achieving the best results in the management of co-
lorectal obstruction due to incurable cancer.
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